Mielóma multiplex: nyitott vizsgálatok itt: Belgium
31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Antwerp, Roeselare
- Age
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036EU 2022-501396-62-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Antwerp, Brugge, Genk, Jette, Liège, Yvoir
- Age
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761EU 2024-519504-27-00Regiszter frissítve: 2026-11-04
2. fázisToborozTrial-stage medicine
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Edegem, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552EU 2023-504581-29-00Regiszter frissítve: 2026-11-03
4. fázisToborozTrial-stage medicine
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Edegem, Gent, Leuven
- Age
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781EU 2023-505530-10-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Anderlecht, Antwerp, Gent, Kortrijk, Leuven
- Age
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222EU 2023-503442-30-00Regiszter frissítve: 2026-11-03
1. fázisToborozTrial-stage medicine
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Edegem, Gent, Liège
- Age
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335EU 2023-503679-12-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Antwerp, Genk, Ghent, Sint-Niklaas
- Age
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Edegem, Gent, Sint-Lambrechts-Woluwe, Yvoir
- Age
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479EU 2024-515279-37-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Brugge, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Yvoir
- Age
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020EU 2024-514139-50-00Regiszter frissítve: 2026-10-27
1/2. fázisToborozTrial-stage medicine
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Gent, Leuven, Liège
- Age
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960EU 2024-517140-65-00Regiszter frissítve: 2026-10-27
1/2. fázisToborozTrial-stage medicine
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Antwerp, Brussels
- Age
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108EU 2024-511454-45-00Regiszter frissítve: 2026-10-26
3. fázisToborozTrial-stage medicine
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Edegem, Ghent, Liège, Roeselare
- Age
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264EU 2026-525626-38-00Regiszter frissítve: 2026-10-14
3. fázisToborozTrial-stage medicine
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Where
- Hasselt, La Louvière, Leuven, Liège, Roeselare
- Age
- 18 év and over
- People
- 1594 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT05243797EU 2023-510384-36-00Regiszter frissítve: 2026-10-07
3. fázisToborozTrial-stage medicine
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- Where
- Anderlecht, Charleroi, Liège, Sint-Lambrechts-Woluwe, Yvoir
- Age
- 18 év to 69 év
- People
- 824 worldwide
- Run by
- Intergroupe Francophone du Myelome
See details and how to joinNCT06918002EU 2024-516418-39-00Regiszter frissítve: 2026-09-30
No phaseToborozResearch participation
Study on the Clinical Efficacy of Teclistamab and Talquetamab
- Where
- Bonheiden, Brussels, Charleroi, Edegem, Ghent, Hasselt, Hornu, Kortrijk, Leuven, Liège, Mons, Roeselare, Sint-Niklaas, Yvoir
- Age
- 18 év and over
- People
- 100
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06477783Regiszter frissítve: 2026-09-25
3. fázisToborozResearch participation
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Edegem, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00EU 2023-510173-34-00Regiszter frissítve: 2026-09-11
1/2. fázisToborozResearch participation
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
- Where
- Edegem, Gent, Leuven
- Age
- 18 év and over
- People
- 90 worldwide
- Run by
- University Of Antwerp
See details and how to join2022-501811-14-00EU 2022-501811-14-00Regiszter frissítve: 2026-09-02
1. fázisToborozResearch participation
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
- Where
- Gent, Jette
- Age
- 18 év and over
- People
- 45 worldwide
- Run by
- Genentech Inc.
See details and how to join2023-503404-89-00EU 2023-503404-89-00Regiszter frissítve: 2026-08-24
3. fázisToborozTrial-stage medicine
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Charleroi, Yvoir
- Age
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236EU 2023-509208-14-00Regiszter frissítve: 2026-08-24
3. fázisToborozTrial-stage medicine
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Boussu, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Verviers, Yvoir
- Age
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575EU 2023-507871-23-00Regiszter frissítve: 2026-08-24
1/2. fázisToborozResearch participation
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Gent, Leuven, Liège
- Age
- 18 év and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00EU 2025-525105-20-00Regiszter frissítve: 2026-07-15
2. fázisToborozTrial-stage medicine
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Where
- Antwerp, Brasschaat, Brugge, Herentals, Mechelen, Roeselare
- Age
- 18 év and over
- People
- 116 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06140524EU 2023-505242-25-00Regiszter frissítve: 2026-07-08
No phaseToborozResearch participation
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Anderlecht, Brussels, Woluwe-Saint-Lambert
- Age
- 65 év and over
- People
- 31
- Run by
- Jules Bordet Institute
See details and how to joinNCT07674498Regiszter frissítve: 2026-06-29
No phaseToborozResearch participation
"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
- Where
- Brussels
- Age
- 18 év and over
- People
- 45
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06988020Regiszter frissítve: 2026-04-24
3. fázisToborozTrial-stage medicine
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Roeselare
- Age
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101EU 2024-516030-35-00Regiszter frissítve: 2026-04-22
Minden vizsgálat (Mielóma multiplex) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.